

Hepatitis C virus: a hidden epidemic

Market landscape 2017


approx. **71 million** people are infected¹

only 20% have been diagnosed

only 7% have received treatment

overall **80%** of the disease burden is in LMICs

HCV IS ON THE RISE



SIX KEY OBSTACLES TO TACKLING HCV

1 LACK OF FUNDING
5/29 countries surveyed have dedicated national HCV budget sufficient to meet or exceed the WHO 2020 targets.

2 LIMITED LAB NETWORKS
Limited laboratory networks negatively impact the scale-up of HCV diagnostics and treatment in many high-burden countries.

3 TOO FEW HEALTHCARE WORKERS
Few frontline healthcare workers are assessing patients for risk of HCV and referring for appropriate diagnosis.

4 INSUFFICIENT DATA
Most countries do not track the volume or yields of screening or viral load tests at a national level, impeding the development of well-informed country strategies, the proper use of diagnostic commodities, and effective price negotiations with suppliers.

5 LACK OF STRATEGY
Few countries have concrete diagnostic targets or scale-up plans for HCV that operationalize the WHO HCV diagnosis targets.

6 LOW PUBLIC AWARENESS OF HCV
Education and awareness programmes in-country are critical to improving the general public's knowledge and reduce stigma associated with HCV, leading to increased demand for testing and improved case-finding.

"Every country in the world has committed to eliminating viral hepatitis by 2030 [but] we are missing a crucial piece of the puzzle. Of the 325 million people living with viral hepatitis, 300 million are still unaware. Without finding the undiagnosed and linking them to care, elimination will remain nothing but a pipe dream." **Raquel Peck**, World Hepatitis Alliance CEO

WHO 2015-2030 Viral Hepatitis Strategy Aims for:



If implemented, this would avert **2.1m HCV-associated deaths**

Total need for screening tests (either lab-based immunoassays or RDTs) over the next 5 years for high-burden LMICs is estimated to be **826 million tests**.



Total need for confirmation and monitoring tests over the next 5 years for high-burden LMICs is estimated at **31 million tests**.



Data from a 2017 market intelligence analysis of HCV diagnostic products covering 29 LMICs, providing 5-year forecasts on need and demand for screening, confirmatory and monitoring tests, and outlining the elements driving the projections and the factors that will allow countries to diagnose more patients.

Full market intelligence report available at: www.finddx.org/publication/hcv-diagnostics-market-intelligence-report-2017

Report developed in collaboration with CHAI and with support from Unitaid



¹ World Health Organization. Global Hepatitis Report, 2017. 2017: Geneva. <http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1>. Accessed 22 June 2017. HCV, hepatitis C virus; LMICs, low- and middle-income countries; RDT, rapid diagnostic test; WHO, World Health Organization.